Mitomycin C (MC), a quinone-containing bioreductive alkylating agent, is cytotoxic to aerobic EMT6 tumor cells despite the fact that little bioactivation of MC occurs in EMT6 cell homogenates in the presence of O2. Because spontaneous activation of MC at acidic pH has been reported in chemical systems, aerobic EMT6 tumor cells were incubated in serum-free 2-(N-morpholino)ethanesulfonic acid or N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid buffer at pH 5.7, 6.4, and 7.5 and exposed to MC for 2 h. As the extracellular pH was lowered, MC-induced DNA-DNA cross-linking, as measured by alkaline elution techniques, was enhanced. This effect was dose dependent at the three pH values tested. Measurement of intracellular pH by flow cytometric analysis indicated that the decrease in extracellular pH was paralleled by a fall in intracellular pH. The alteration of the extracellular pH had no effect on the colony-forming ability of control cells. The survival of cells treated with MC, however, was decreased as the pH was lowered. These data suggest that the intracellular and/or the extracellular pH is an important determinant of MC activity in aerobic EMT6 tumor cells.

Download full-text PDF

Source

Publication Analysis

Top Keywords

emt6 tumor
16
tumor cells
16
aerobic emt6
12
cells
6
emt6
5
dependence mitomycin
4
mitomycin c-induced
4
c-induced cross-linking
4
cross-linking activity
4
activity emt6
4

Similar Publications

Background: Granzyme B (GrB) is a key effector molecule, delivered by cytotoxic T lymphocytes and natural killer cells during immune surveillance to induce cell death. Fusion proteins and immunoconjugates represent an innovative therapeutic approach to specifically deliver a deadly payload to target cells. Epithelial membrane protein-2 (EMP2) is highly expressed in invasive breast cancer (BC), including triple-negative BC (TNBC), and represents an attractive therapeutic target.

View Article and Find Full Text PDF

Interleukin-12 (IL-12) is a potent NK cell-stimulating cytokine, but the presence of immunosuppressive myeloid cells such as myeloid-derived suppressor cells (MDSC) can inhibit IL 12-induced NK-cell cytotoxicity. Thus, we hypothesized that trabectedin, a myeloid cell-depleting agent, would improve the efficacy of IL-12 in triple-negative breast cancer (TNBC). In vitro treatment of healthy donor NK cells with trabectedin increased expression of the activation marker CD69 and mRNA expression of T BET (Tbx21), the cytotoxic ligands TRAIL (TNFSF10) and Fas ligand (FASLG) and the dendritic cell (DC)-recruiting chemokine lymphotactin (XCL1).

View Article and Find Full Text PDF

Doxorubicin (DOXO) is a widely used anti-cancer agent, yet the precise mechanism underlying the induction of tumor cell death remains unclear. This study aimed to elucidate new mechanisms by which doxorubicin induces apoptosis in the EMT6 mouse breast carcinoma cell line. The role of doxorubicin was assessed using the XTT assay.

View Article and Find Full Text PDF

IMPDH inhibitors upregulate PD-L1 in cancer cells without impairing immune checkpoint inhibitor efficacy.

Acta Pharmacol Sin

November 2024

Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, Institute of Pharmacology and Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.

Tumor cells are characterized by rapid proliferation. In order to provide purines for DNA and RNA synthesis, inosine 5'-monophosphate dehydrogenase (IMPDH), a key enzyme in the de novo guanosine biosynthesis, is highly expressed in tumor cells. In this study we investigated whether IMPDH was involved in cancer immunoregulation.

View Article and Find Full Text PDF

LCP1 promotes ovarian cancer cell resistance to olaparib by activating the JAK2/STAT3 signalling pathway.

Cancer Biol Ther

December 2024

Department of Gynecology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China.

Article Synopsis
  • Resistance to PARP inhibitors in ovarian cancer is a significant issue, with LCP1 identified as a key player in tumor progression and linked to the JAK2/STAT3 signaling pathway that enhances metastatic ability and chemoresistance.* -
  • In experiments, a cell line resistant to olaparib was created, revealing that LCP1 levels were higher in these cells, and knocking down LCP1 diminished their resistance to the drug.* -
  • The study suggests that targeting LCP1 could be a new approach for treating ovarian cancer patients resistant to olaparib by disrupting the JAK2/STAT3 pathway and its contribution to epithelial-mesenchymal transition.*
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!